Watchlist Manager

Watchlist

Price: 28.2 CNY -2.12% Market Closed

Market Cap: ¥13.2B

V	Vcanbio Cell & Gene Engineering Corp Ltd SSE:600645	CN

Balance Sheet

Currency: CNY

	Dec-2001	Dec-2002	Dec-2003	Dec-2004	Dec-2005	Dec-2006	Dec-2007	Dec-2008	Dec-2009	Dec-2010	Dec-2011	Dec-2012	Dec-2013	Dec-2014	Dec-2015	Dec-2016	Dec-2017	Dec-2018	Dec-2019	Dec-2020	Dec-2021	Dec-2022	Dec-2023	Dec-2024
Assets
Cash & Cash Equivalents	66	40	61	42	43	103	73	197	332	460	587	624	816	352	545	284	476	585	632	1 060	1 190	1 381	1 581	1 525
Cash	0	0	0	0	0	0	0	0	0	0	0	1	2	5	0	0	0	0	0	0	1 190	1 381	1 575	1 525
Cash Equivalents	66	40	61	42	43	103	73	197	332	460	587	623	814	348	544	284	476	585	632	1 060	0	0	6	0
Short-Term Investments	29	2	2	0	0	0	22	32	0	43	0	0	0	367	0	129	0	0	402	0	0	0	0	0
Total Receivables	296	193	188	131	126	97	75	60	35	26	33	69	65	158	204	269	443	555	585	549	541	624	651	679
Accounts Receivables	28	24	29	19	24	34	35	29	28	20	26	41	51	119	163	189	312	415	467	443	456	523	567	609
Other Receivables	268	169	159	112	101	64	40	31	7	6	7	28	14	39	41	80	131	139	118	106	84	101	84	70
Inventory	104	89	75	52	19	41	49	42	34	20	21	27	29	57	62	64	182	188	219	222	227	248	248	232
Other Current Assets	10	32	2	10	27	14	12	3	3	7	9	26	11	18	82	52	86	61	69	84	73	57	28	20
Total Current Assets	505	356	327	235	215	256	230	333	404	555	650	747	921	953	892	799	1 186	1 389	1 906	1 915	2 030	2 310	2 508	2 456
PP&E Net	117	110	135	155	173	217	211	196	172	140	133	212	243	342	593	776	794	723	755	734	776	772	721	693
PP&E Gross	117	110	135	155	173	217	211	196	172	140	133	212	243	342	593	776	794	723	755	734	776	772	721	693
Accumulated Depreciation	87	91	47	60	64	49	66	84	96	90	107	134	161	187	215	246	337	354	385	423	512	560	647	758
Intangible Assets	33	31	108	124	50	62	54	49	43	33	27	28	43	67	103	113	182	226	156	151	149	138	147	159
Goodwill	0	0	0	0	0	0	0	0	0	0	0	40	40	576	576	600	1 245	1 018	987	723	703	703	703	703
Note Receivable	0	0	0	0	0	0	0	0	0	6	4	2	16	39	49	83	106	109	87	69	66	52	37	28
Long-Term Investments	115	56	55	52	50	50	91	72	80	36	29	38	34	254	403	400	573	720	793	1 062	1 082	1 062	1 035	945
Other Long-Term Assets	11	12	11	4	1	2	2	2	2	2	10	167	188	186	201	232	329	259	204	226	228	247	260	265
Other Assets	0	0	0	0	0	0	0	0	0	0	0	40	40	576	576	600	1 245	1 018	987	723	703	703	703	703
Total Assets	781 N/A	565 -28%	636 +13%	570 -10%	488 -14%	586 +20%	589 +0%	652 +11%	700 +7%	772 +10%	851 +10%	1 233 +45%	1 485 +20%	2 417 +63%	2 816 +17%	3 004 +7%	4 415 +47%	4 443 +1%	4 889 +10%	4 880 0%	5 033 +3%	5 285 +5%	5 411 +2%	5 249 -3%
Liabilities
Accounts Payable	42	22	24	19	15	20	28	23	11	6	6	33	21	30	35	53	59	70	73	81	70	105	103	115
Accrued Liabilities	1	1	3	6	6	14	6	5	9	14	14	15	13	26	35	42	74	76	77	94	139	135	148	156
Short-Term Debt	208	107	111	100	65	56	7	6	6	0	0	0	0	0	0	20	2	39	0	9	17	9	16	3
Current Portion of Long-Term Debt	0	0	0	0	0	5	7	0	0	0	0	0	0	0	13	19	19	21	84	0	23	28	30	44
Other Current Liabilities	62	75	129	151	219	277	314	357	397	471	559	901	788	1 148	977	1 015	1 080	1 063	1 116	1 116	1 147	1 195	1 184	1 171
Total Current Liabilities	314	205	266	276	306	373	362	391	423	491	579	949	822	1 204	1 059	1 149	1 233	1 268	1 350	1 300	1 396	1 471	1 482	1 487
Long-Term Debt	54	4	4	4	16	11	4	0	0	0	0	0	0	0	38	79	141	119	35	38	48	102	86	68
Deferred Income Tax	0	0	0	0	0	0	1	0	0	0	0	0	0	3	15	2	25	20	17	14	35	35	23	13
Minority Interest	54	54	63	84	101	107	99	130	111	112	113	135	159	124	128	164	208	212	107	106	69	98	115	64
Other Liabilities	0	1	1	1	1	21	36	5	38	36	3	3	3	54	23	22	51	53	26	25	23	23	22	21
Total Liabilities	421 N/A	265 -37%	334 +26%	364 +9%	424 +16%	512 +21%	502 -2%	526 +5%	572 +9%	639 +12%	695 +9%	1 087 +56%	984 -10%	1 384 +41%	1 263 -9%	1 416 +12%	1 658 +17%	1 671 +1%	1 535 -8%	1 483 -3%	1 570 +6%	1 729 +10%	1 727 0%	1 654 -4%
Equity
Common Stock	250	250	250	250	250	250	325	325	325	325	325	325	349	375	386	386	385	440	468	468	468	468	468	468
Retained Earnings	31	34	43	139	282	275	263	224	222	214	190	179	171	136	73	110	667	608	561	688	514	401	294	194
Additional Paid In Capital	89	94	95	96	96	100	25	25	25	21	21	0	324	793	1 060	1 093	3 046	2 928	3 401	3 378	3 383	3 384	3 377	3 374
Unrealized Security Profit/Loss	9	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	149	70	85	88
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	1	0	0	0	0	0	0	200
Other Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	37	1	6	13	46	239	23	34	48	60
Total Equity	361 N/A	300 -17%	302 +1%	206 -32%	64 -69%	75 +17%	87 +16%	126 +45%	128 +2%	133 +3%	156 +18%	147 -6%	502 +242%	1 033 +106%	1 554 +50%	1 588 +2%	2 757 +74%	2 773 +1%	3 354 +21%	3 396 +1%	3 463 +2%	3 556 +3%	3 684 +4%	3 595 -2%
Total Liabilities & Equity	781 N/A	565 -28%	636 +13%	570 -10%	488 -14%	586 +20%	589 +0%	652 +11%	700 +7%	772 +10%	851 +10%	1 233 +45%	1 485 +20%	2 417 +63%	2 816 +17%	3 004 +7%	4 415 +47%	4 443 +1%	4 889 +10%	4 880 0%	5 033 +3%	5 285 +5%	5 411 +2%	5 249 -3%
Shares Outstanding
Common Shares Outstanding	325	325	325	325	325	325	325	325	325	325	325	325	349	375	386	386	385	440	468	468	468	468	468	456

Income Statement Balance Sheet Cash Flow Statement

Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645

Balance Sheet

Balance Sheet Decomposition
Vcanbio Cell & Gene Engineering Corp Ltd

Balance Sheet
Vcanbio Cell & Gene Engineering Corp Ltd

See Also

Company

Help

Tools

Stocks

Vcanbio Cell & Gene Engineering Corp Ltd SSE:600645

Balance Sheet

Balance Sheet Decomposition Vcanbio Cell & Gene Engineering Corp Ltd

Balance Sheet Vcanbio Cell & Gene Engineering Corp Ltd

See Also

Company

Help

Tools

Stocks

Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645

Balance Sheet Decomposition
Vcanbio Cell & Gene Engineering Corp Ltd

Balance Sheet
Vcanbio Cell & Gene Engineering Corp Ltd